RT Journal Article
SR Electronic
T1 The impact of COVID-19 on prescribing of pancreatic enzyme replacement therapy for people with unresectable pancreatic cancer in England. A cohort study using OpenSafely-TPP
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.08.22277317
DO 10.1101/2022.07.08.22277317
A1 Lemanska, Agnieszka
A1 Andrews, Colm
A1 Fisher, Louis
A1 Butler-Cole, Ben
A1 Mehrkar, Amir
A1 Roberts, Keith J
A1 Goldacre, Ben
A1 Walker, Alex J
A1 The OpenSAFELY Collaborative
A1 MacKenna, Brian
YR 2022
UL http://medrxiv.org/content/early/2022/08/31/2022.07.08.22277317.abstract
AB Background Cancer treatments were variably disrupted during the COVID-19 pandemic. Despite UK national guidelines recommending pancreatic enzyme replacement therapy to all people with unresectable pancreatic cancer, observational studies demonstrate under-prescribing.Aim To investigate the impact of the COVID-19 pandemic on the prescribing of pancreatic enzyme replacement to people with unresectable pancreatic cancer.Methods With the approval of NHS England, we conducted a cohort study using 24 million health records through the OpenSAFELY-TPP research platform. We modelled the effect of COVID-19 with multivariable linear regression.Results We found no reduction in pancreatic enzyme replacement therapy during the COVID-19 pandemic. Overall, since 2015, the rates of prescribing increased steadily over time by 1% every year. The national rates ranged from 41% in 2015 to 48% in 2022. There was substantial regional variation. The highest rates of 50% to 60% were in the West Midlands and the lowest (20% to 30%) were in London.Conclusions In contrast to many other treatments, prescribing of pancreatic enzyme replacement therapy was not affected during the COVID-19 pandemic. Although overall rates increased over time, substantial under-prescribing existed at the end of this study (March 2022). At just under 50% in 2022, the rates were still below the recommended 100% standard. Prior work evaluating quality of care in this area relied on manual audits which come at increased cost and reduced frequency of updates. With the methodological advantage of OpenSAFELY, we established an automated audit which allows for regular updates.What is already known on this topicCancer treatments were disrupted by the COVID-19 pandemic.Pancreatic enzyme replacement therapy (PERT) is underused in people with pancreatic cancer.What this study addsPrescribing of PERT was not affected by the COVID-19 disruption.Since 2015, the rates of PERT in England increased by 1% every year.At just under 50% in 2022, the national rates were significantly below the recommended 100% standard for people with unresectable pancreatic cancer.We also showed substantial regional variation.How this study might affect research, practice or policyResearch is needed to understand barriers to prescribing of PERT.Our automated audit will allow regular data updates for the evaluation of healthcare interventions to improve prescribing of PERT.Competing Interest StatementBG received research funding from the Laura and John Arnold Foundation, the NHS National Institute for Health Research (NIHR), the NIHR School of Primary Care Research, NHS England, the NIHR Oxford Biomedical Research Centre, the Mohn-Westlake Foundation, NIHR Applied Research Collaboration Oxford and Thames Valley, the Wellcome Trust, the Good Thinking Foundation, Health Data Research UK, the Health Foundation, the World Health Organisation, UKRI MRC, Asthma UK, the British Lung Foundation, and the Longitudinal Health and Wellbeing strand of the National Core Studies programme; he is a Non-Executive Director at NHS Digital; he also receives personal income from speaking and writing for lay audiences on the misuse of science. BMK is employed as a pharmacist by NHS England and seconded to the Bennett Institute.Funding StatementThis work was jointly funded by the Wellcome Trust (222097/Z/20/Z); MRC (MR/V015757/1, MC_PC-20059, MR/W016729/1); NIHR (NIHR135559, COV-LT2-0073), and Health Data Research UK (HDRUK2021.000, 2021.0157). This work was funded by Medical Research Council (MRC) grant reference MR/W021390/1 as part of the postdoctoral fellowship awarded to AL and undertaken at the Bennett Institute, University of Oxford. The views expressed are those of the authors and not necessarily those of the NIHR, NHS England, UK Health Security Agency (UKHSA) or the Department of Health and Social Care. Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Health Research Authority (Research Ethics Committee reference 20/LO/0651) and the London School of Hygiene and Tropical Medicine (London, UK) Ethics Board (reference 21863).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDetailed pseudonymised patient data are potentially re-identifiable and therefore not shared. The process for external users to request access to data via the OpenSAFELY platform is described on opensafely.org. https://www.opensafely.org/ COVID-19Coronavirus disease 2019EHRElectronic healthcare recordsGPGeneral practiceNHSNational Health ServicePERTPancreatic enzyme replacement therapyRICOCHETReceipt of curative resection or palliative care for hepatopancreaticobiliary tumours